Literature DB >> 10343529

Reduced purine 5'-nucleotidase activity in lymphocytes of patients with systemic lupus erythematosus: results of a pilot study.

J N Stolk1, D G de Koning, A H Pennings, R A De Abreu, L B van de Putte, A M Boerbooms.   

Abstract

OBJECTIVE: To investigate purine metabolism in patients with systemic lupus erythematosus (SLE) for possible abnormalities that might be related to their overall impaired immune function.
METHODS: This pilot study included 17 patients with SLE (2 men, 15 women). Enzyme activities of the purine enzymes 5'-nucleotidase (5'NT), purine nucleoside phosphorylase (PNP), and hypoxanthine-guanine-phosphoribosyltransferase (HGPRT) were measured in peripheral blood mononuclear cells (PBMC) and also in fractions of T cells (differentiation antigen CD3+) (n = 12) and B cells (CD19+) (n = 9). The activity of the thiopurine enzyme thiopurine-methyltransferase (TPMT) was measured in red cell lysate. Routine blood tests and indices of disease activity were measured as well. Results were compared with those of healthy volunteers.
RESULTS: Compared with their controls, the female SLE patients had a more than 50% reduced activity of 5'NT in the T cell fraction (p = 0.001) and in PBMC (p < 0.000). 5'NT activity was also lower in B cells, but this was not statistically significant. Enzyme activities did not correlate with indices of disease activity, disease duration or the B cell/T cell ratio and no influence of medication was found.
CONCLUSION: Reduced lymphocyte 5'NT activity is a novel finding in SLE. These results indicate that purine metabolism in SLE may be disturbed. Consequences of a low 5'NT activity may be an intracellular accumulation of (deoxy)purine nucleotides and a reduction of adenosine production. It is hypothesised that these factors may play a part in the overall impaired immune function and in the chronicity of inflammation in SLE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10343529      PMCID: PMC1752826          DOI: 10.1136/ard.58.2.122

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  3 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  Purine enzymes in patients with rheumatoid arthritis treated with methotrexate.

Authors:  A E van Ede; R F J M Laan; R A De Abreu; A B J Stegeman; L B A van de Putte
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

3.  Adenosine deaminase and 5'nucleotidase activities in peripheral blood T cells of multiple sclerosis patients.

Authors:  S Vivekanandhan; C C Soundararajan; M Tripathi; M C Maheshwari
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.